Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C (Q79561534)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

title

Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Peter Liljeström

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

10

Giuseppe Pantaleo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

14

Mariano Esteban

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

13

Ralf Wagner

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

2

Jose Luis Nájera

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1

Carmen Elena Gómez

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Marie-Joelle Frachette

9

object named as

Marie-Joelle Frachette

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

6

Linda Kostic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

author name string

Victoria Jiménez

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Kurt Bieler

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Shirin Heidari

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Margaret Chen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Hans Wolf

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

publication date

6 December 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

page(s)

1969-1992

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?

24 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Estimated Global Distribution and Regional Spread of HIV-1 Genetic Subtypes in the Year 2000

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Characterization of full-length HIV type 1 subtype C sequences from South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

HIV vaccine design and the neutralizing antibody problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Antibody neutralization and escape by HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Prospects for an AIDS vaccine: three big questions, no easy answers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Strategies for an HIV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Non-replicating viral vector-based AIDS vaccines: interplay between viral vectors and the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Progress towards an HIV-1 subtype C vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

NYVAC: a highly attenuated strain of vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Compact, synthetic, vaccinia virus early/late promoter for protein expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Aromatic interactions define the binding of the alphavirus spike to its nucleocapsid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Quantification of antigen specific CD8+ T cells using an ELISPOT assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

A review of vaccine research and development: human enteric infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8(+) T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Immunodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Studies in subjects with long-term nonprogressive human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Clinical trials of HIV vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

inferred from DOI database lookup

7 January 2021

based on heuristic

Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

inferred from DOI database lookup

7 January 2021

based on heuristic

Two-helper RNA system for production of recombinant Semliki forest virus particles.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.051

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2006.11.051

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17224219%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference